ClinicalTrials.gg
CompletedNCT05631626Updated Jul 2, 2026Results posted

Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.

A Phase 3 interventional study of CTx-1301 - Dexmethylphenidate 25mg and CTx-1301 - Dexmethylphenidate 37.5mg in ADHD, ADHD - Combined Type and Attention Deficit Hyperactivity Disorder Combined, sponsored by Cingulate Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Cingulate Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
558th of 706
26 · median 70
Started
2022
with 30 others
Phase 3
121 of 807
4 open now
Registered
678th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 558th largest by enrollment of the 706 interventional ones that give a count, is one of 31 that started in 2022, is one of 121 in phase 3, and was the 678th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.

Read the detailed description

A single-center, dose-optimized, double-blind, randomized, placebo-controlled, parallel efficacy and safety laboratory classroom study with CTx-1301 in approximately 25 adults aged 18 to 55 years with ADHD. The study will be comprised of a screening period, a dose-optimization phase, a double-blind randomized phase, and a safety follow-up phase. Subjects will undergo a screening visit prior to entering a 5-week dose-optimization phase. During the dose-optimization phase subjects will have weekly visit and will be titrated to doses ranging between 25mg-50mg of CTx-1301. Eligible subjects will be randomized to their optimal dose or placebo in a 1:1 ratio after completing a practice Adult Laboratory Classroom (ALC) visit with 4 PERMP assessments. Subjects will take their assigned/randomized dose over the following 7-day period. On the 7th day subjects will complete a full ALC visit. The duration of the full ALC visit will be approximately 17 hours. Subjects will have an in-clinic safety follow-up visit within 7 days after the full adult laboratory classroom visit.

03

Conditions studied

  • ADHD
  • ADHD - Combined Type
  • Attention Deficit Hyperactivity Disorder Combined
  • Attention Deficit Hyperactivity Disorder
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between 18 and 55 years of age (inclusive) at the time of consent.
  2. Subject must have a (BMI) ≥18.5 and ≤40.
  3. Subject is unsatisfied with his/her current pharmacological therapy for treatment of ADHD or not currently receiving pharmacological therapy for ADHD. Inclusion of subjects who are naïve to pharmacological therapy for ADHD is permitted.
  4. Negative serum beta-human chorionic gonadotropin (hCG) pregnancy test for subjects of and must agree to remain abstinent or agree to use a highly effective, medically acceptable form of for the time of written or verbal consent and for at least 30 days after the last dose of study drug has been taken (females) unless or surgically sterile. Male subjects with female partners must agree at Screening to remain abstinent or agree to use an effective and medically acceptable form of birth control from Screening to 90 days after the last dose of study drug.
  5. Subject must be in general good health defined as absence of any abnormalities as determined by the Investigator based on physical and neurological examinations, vital signs, ECGs, medical history, and laboratory values (hematology, chemistry, or urinalysis) at Screening. If any of the exams or values are not within the laboratory reference range, the Investigator must review range and determine if clinically relevant. If clinically relevant, the subject is not eligible for the study.
  6. Subject's intellectual function is at an appropriate level, as deemed by the Investigator.
  7. Subjects need to be able to perform at least the basic level of problems on the PERMP pre-test with at least 10 questions answered correctly per page or 2 minutes performed at Visit 2.
  8. Subject must meet - Fifth Edition (DSM-5) criteria for the primary diagnosis of ADHD for any of the three presentations (combined, inattentive, or hyperactive/impulsive presentation) upon clinical evaluation and confirmed by the Mini International Neuropsychiatric Interview for Attention Deficit/Hyperactivity Disorder - Adults (MINI).
  9. Subject must score 24 or higher on the Adult ADHD Investigator Rating Scale (AISRS) at the Screening visit (Visit 1) and Baseline visit (Visit 2) if no ADHD medication is required. For subjects requiring washout of ADHD medications, this criterion refers to a score following washout at the Baseline visit (Visit 2).
  10. Subject must have a score of 4 (moderately ill) or higher on the clinician-administrated Clinical Global Impressions-Severity (CGI-S) scale at Screening. For subjects requiring washout of ADHD medications, this criterion refers to a score at the Baseline visit (Visit 2).
  11. Subject must be able and willing to wash out of all stimulant ADHD medications (except study drug as indicated per protocol), including herbal medication, from 5 days prior to the start of the dose-optimization phase and for the duration of the entire study, defined as completion of the safety follow-up visit. Additionally, subject must be able and willing to wash out from all non-stimulant ADHD medications 21 days prior to the start of the dose optimization phase and for the duration of the entire study, defined as completion of the safety follow-up visit.
  12. Subject must be able to read, write, speak, and understand English and be able to communicate with the Investigator and study coordinator in a satisfactory fashion and complete any study-related materials. Subject must plan to be available for the entire duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. If female and of , the subject must not be pregnant or breastfeeding at any time during the study or for 30 days following the completion of the study. If of child-bearing potential, urine hCG tests will be administered at protocol specified time points. Any positive pregnancy test during the study will exclude them from further participation in the study.
  2. Subject has any psychiatric diagnosis of bipolar I or II disorder, current major depressive disorder, conduct disorder, disruptive mood dysregulation disorder, intellectual disability, obsessive-compulsive disorder, eating disorder, anxiety disorder (including generalized anxiety disorder), any history of psychosis, autism spectrum disorder, Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances, or any other diagnosis/significant medical history that at the discretion of the Investigator excludes the subject from entry into the study.
  3. Subject has evidence of any chronic disease of the central nervous system (CNS) such as tumors, inflammation, seizure disorder, vascular disorder, potential CNS-related disorders that might occur in childhood, or history of persistent neurological symptoms related to a serious head injury.
  4. Subject has any and/or unstable medical abnormality, chronic medical condition, persistent neurological symptoms, history of cardiovascular abnormality, abnormalities of respiratory, hepatic, gastrointestinal, renal, or any disorder or history of a condition that would impact or interfere with drug absorption, distribution, metabolism, or excretion during the study or may interfere with the participants ability to participate in the study.
  5. Subject has family history of early cardiovascular disease or sudden death.
  6. Subject has any history of attempted suicide or clinically significant suicidal ideation based on the Columbia Suicide Severity Rating Scale (C-SSRS) assessment, or answers "yes" to "Suicidal Ideation" item 4 or 5 in the past 3 years on the C-SSRS lifetime/recent assessment at Screening.
  7. Subject has history of seizures, excluding febrile seizures.
  8. Subject has a known primary sleep disorder (e.g., sleep apnea, narcolepsy, etc.)
  9. Subject has a history of moderate to severe hypertension or has a resting sitting systolic blood pressure greater than140 millimeters of mercury (mmHg) or diastolic blood pressure greater than 90 mmHg.
  10. Subject is considered treatment by the Investigator.
  11. Any use of anticonvulsants currently or within the past 2 years.
  12. Uncontrolled thyroid disorder indicated by thyroid stimulating hormone (TSH) ≤0.8 x the lower limit of normal (LLN) or ≥ 1.25 x the (ULN) from the reference laboratory.
  13. Subject has first-degree relatives (biological parent or sibling) with a history of schizophrenia, schizoaffective disorder, bipolar I disorder, or bipolar II disorder.
  14. Subject has history of substance abuse or shows evidence of substance or alcohol use disorder or has a positive urine alcohol or drug screen at Screening. Subjects with positive drug screens may be allowed to continue in the study if the result of the positive drug screen is from prescribed medications and the subject is willing to washout of the medication as required per protocol.
  15. Subject has a history of physical, emotional, or sexual abuse resulting in a current diagnosis of posttraumatic stress disorder.
  16. Previous treatment experience/exposure to CTx-1301.
  17. Subject has a history of allergic reaction or sensitivity to methylphenidate, or any substance contained in CTx-1301 or the placebo drug.
  18. Subject has participated in a laboratory study within 6 months prior to the start of Screening or has participated in any other clinical study with an drug/product within 90 days prior to Screening or is currently participating in another clinical study.
  19. Subject anticipates a move outside the geographic range of the investigative site during the duration of the study period or plans on travel that would not allow compliance to the protocol during the study period.
  20. Subject is unsuitable in any other way to participate in the study, as determined by the Investigator.
  21. Subjects who are family members of the employees at the study center, of the investigator, or those with direct involvement in the proposed study under the direction of that investigator or study center.
  22. Subjects that live in the same household are not allowed to be in the same cohort.

Eligibility Criteria:

Subjects will be required to meet the following criteria at the end of the dose-optimization phase in order to be eligible for the double-blind, randomized treatment phase. These criteria are based on the efficacy and safety observed over the 5-week dose-optimization period.

  1. A minimum of 2 sequential weeks on optimal dose.
  2. A reduction of ≥ 30% of the AISRS from Visit 2 to Visit 7 during the dose optimization phase.
  3. A CGI-I score of 1 or 2 points ("Very Much Improved" or "Much Improved") at the end of the dose optimization phase.
  4. Acceptable tolerability of the optimized CTx-1301 dose during the dose optimization phase.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    25mg CTx-1301 (Dexmethylphenidate tablet)

    All subjects will be titrated to their optimal dose during the dose-optimization phase. The starting dose for all subjects at Day 0 is 25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.

    Drug: CTx-1301 - Dexmethylphenidate 25mg

  • Active comparator
    37.5mg CTx-1301 (Dexmethylphenidate tablet)

    All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg . Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.

    Drug: CTx-1301 - Dexmethylphenidate 37.5mg

  • Active comparator
    50mg CTx-1301 (Dexmethylphenidate tablet)

    All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg . Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.

    Drug: CTx-1301 - Dexmethylphenidate 50mg

  • Placebo comparator
    Placebo

    Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.

    Drug: Placebo

Interventions

  • 25mg CTx-1301 (Dexmethylphenidate tablet)

    Also known as: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg of CTx-1301.

  • 37.5mg CTx-1301 (Dexmethylphenidate tablet)

    Also known as: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg of CTx-1301.

  • 50mg CTx-1301 (Dexmethylphenidate tablet)

    Also known as: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg of CTx-1301.

  • DrugPlacebo

    Placebo

    Also known as: Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.

06

What researchers measure

Primary outcomes

  1. The Primary Efficacy Analysis Will Analyze the Change in PERMP Scores From Baseline (Pre-dose) at Visit 8 to Hour 16 at Visit 8.

    The Permanent Product Measure of Performance-Correct (PERMP-C) is an objective, validated, skill-adjusted 10-minute math test that measures attention and accuracy in ADHD. Performance is measured by the number of math problems answered correctly. The minimum possible score is 0. The highest possible score is 400, with higher scores mean higher performance and less severe ADHD symptoms.

    Time frame: Average of the change of the PERMP-C scores from baseline defined as pre-dose score at Visit 8 which was at end of 7-day double-blind period to PERMP-C scores at hour 16 at Visit 8.

Secondary outcomes

  1. Key Secondary Analysis Will Analyze the Change in PERMP Scores From Baseline at Each Time Point During the Laboratory Environment at Visit 8.

    The Permanent Product Measure of Performance-Correct (PERMP-C) is an objective, validated, skill-adjusted 10-minute math test that measures attention and accuracy in ADHD. Performance is measured by the number of math problems answered correctly. The minimum possible score is 0. The highest possible score is 400, with higher scores mean higher performance and less severe ADHD symptoms.

    Time frame: Average of the change of the PERMP-C scores from baseline defined as pre-dose score at Visit 8 which was at end of 7-day double-blind period to PERMP-C scores at hours .5,1,3,6,9,12,13,14,15, and 16.

  2. Key Secondary Analysis Will Analyze the Change From Baseline (Pre-dose at Visit 2) of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8.

    The Clinical Global Impression-Severity (CGI-S) scale is a 7-point clinician-rated tool that measures the overall severity of a subject's illness. It rates subjects from 1 (normal) to 7 (among the most extremely ill). A higher score means a worse outcome.

    Time frame: Baseline (pre-dose at Visit 2) to Visit 8 (approximately 6 weeks).

Other outcomes

  1. Safety - Incidence of TEAEs

    Treatment Emergent Adverse Events (TEAEs) will be evaluated at each visit

    Time frame: Screening (Visit 1) to Visit 9 (approximately 7-11 weeks, depending on screening window)

  2. The Purpose of This Study is to Estimate the Effect Size of Treatment on the PERMP Instrument in an Adult ADHD Population as Defined by the Inclusion/Exclusion Criteria.

    The purpose of this study is to estimate the effect size of treatment on the PERMP instrument in an adult ADHD population as defined by the inclusion/exclusion criteria. The Permanent Product Measure of Performance (PERMP) is an objective, validated, skill-adjusted 10-minute math test that measures attention in ADHD. The PERMP correct score comprises the number of math problems answered correctly. A higher PERMP score indicates better performance.Though primary and secondary endpoints are defined in accordance with International Conference on Harmonization (ICH) E9 guidelines, this study is not intended to demonstrate statistical significance via treatment group comparisons.

    Time frame: Baseline (pre-dose) at Visit 8 then post-dose at hours .5,1,3,6,9,12,13,14,15, and 16.

07

Results

Posted Jul 2, 2026

Participant flow

A total of 26 subjects were enrolled, of which 21 were randomized to double-blind, placebo controlled treatment at one study center from December 29, 2022 to June 6, 2023.

Screening/Dose Optimization (9 Weeks)
Participant flow — Screening/Dose Optimization (9 Weeks)
MilestoneCTx-1301 (Dexmethylphenidate Tablet) Dose Optimization PhaseCTx-1301 (Dexmethylphenidate Tablet) Double-Blind PeriodPlacebo
Started2600
Completed2100
Not completed500
Double-Blind Period (7 Days)
Participant flow — Double-Blind Period (7 Days)
MilestoneCTx-1301 (Dexmethylphenidate Tablet) Dose Optimization PhaseCTx-1301 (Dexmethylphenidate Tablet) Double-Blind PeriodPlacebo
Started01110
Completed01110
Not completed000

Outcome measures

PrimaryThe Primary Efficacy Analysis Will Analyze the Change in PERMP Scores From Baseline (Pre-dose) at Visit 8 to Hour 16 at Visit 8.

The Permanent Product Measure of Performance-Correct (PERMP-C) is an objective, validated, skill-adjusted 10-minute math test that measures attention and accuracy in ADHD. Performance is measured by the number of math problems answered correctly. The minimum possible score is 0. The highest possible score is 400, with higher scores mean higher performance and less severe ADHD symptoms.

Time frame:
Average of the change of the PERMP-C scores from baseline defined as pre-dose score at Visit 8 which was at end of 7-day double-blind period to PERMP-C scores at hour 16 at Visit 8.
Reported as:
Least squares mean · score on a scale
The Primary Efficacy Analysis Will Analyze the Change in PERMP Scores From Baseline (Pre-dose) at Visit 8 to Hour 16 at Visit 8.
score on a scaleCTx-1301 (Dexmethylphenidate Tablet)Placebo
The Primary Efficacy Analysis Will Analyze the Change in PERMP Scores From Baseline (Pre-dose) at Visit 8 to Hour 16 at Visit 8.24.94 (15.474 to 34.415)13.09 (3.149 to 23.033)
SecondaryKey Secondary Analysis Will Analyze the Change in PERMP Scores From Baseline at Each Time Point During the Laboratory Environment at Visit 8.

The Permanent Product Measure of Performance-Correct (PERMP-C) is an objective, validated, skill-adjusted 10-minute math test that measures attention and accuracy in ADHD. Performance is measured by the number of math problems answered correctly. The minimum possible score is 0. The highest possible score is 400, with higher scores mean higher performance and less severe ADHD symptoms.

Time frame:
Average of the change of the PERMP-C scores from baseline defined as pre-dose score at Visit 8 which was at end of 7-day double-blind period to PERMP-C scores at hours .5,1,3,6,9,12,13,14,15, and 16.
Reported as:
Least squares mean · score on a scale
Key Secondary Analysis Will Analyze the Change in PERMP Scores From Baseline at Each Time Point During the Laboratory Environment at Visit 8.
score on a scaleCTx-1301 (Dexmethylphenidate Tablet)Placebo
Hour .514.4 (7.02 to 21.78)7.2 (-0.59 to 14.91)
Hour 119.2 (11.86 to 26.55)10.2 (2.46 to 17.89)
Hour 318.6 (8.27 to 28.97)7.2 (-3.65 to 18.08)
Hour 626.8 (18.14 to 33.45)11.1 (2.04 to 20.21)
Hour 924.7 (13.71 to 35.63)7.9 (-3.64 to 19.36)
Hour 1221.4 (9.51 to 33.27)14.1 (1.60 to 26.54)
Hour 1327.8 (14.33 to 41.33)18.7 (4.51 to 32.86)
Hour 1432.4 (17.67 to 47.03)19.6 (4.20 to 35.03)
Hour 1535.3 (20.23 to 50.44)16.7 (0.87 to 32.59)
Hour 1628.8 (13.31 to 44.37)18.3 (1.97 to 34.58)
SecondaryKey Secondary Analysis Will Analyze the Change From Baseline (Pre-dose at Visit 2) of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8.

The Clinical Global Impression-Severity (CGI-S) scale is a 7-point clinician-rated tool that measures the overall severity of a subject's illness. It rates subjects from 1 (normal) to 7 (among the most extremely ill). A higher score means a worse outcome.

Time frame:
Baseline (pre-dose at Visit 2) to Visit 8 (approximately 6 weeks).
Reported as:
Least squares mean · score on a scale
Key Secondary Analysis Will Analyze the Change From Baseline (Pre-dose at Visit 2) of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8.
score on a scaleCTx-1301 (Dexmethylphenidate Tablet)Placebo
Key Secondary Analysis Will Analyze the Change From Baseline (Pre-dose at Visit 2) of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8.-1.1 (-1.40 to -0.79)-0.1 (-0.42 to 0.23)
Other pre-specifiedSafety - Incidence of TEAEs

Treatment Emergent Adverse Events (TEAEs) will be evaluated at each visit

Time frame:
Screening (Visit 1) to Visit 9 (approximately 7-11 weeks, depending on screening window)
Reported as:
Count of participants · Participants
Safety - Incidence of TEAEs
ParticipantsCTx-1301 (Dexmethylphenidate Tablet) Dose Optimization PhaseCTx-1301 (Dexmethylphenidate Tablet) Double-Blind Treatment PhasePlacebo Double-Blind Treatment Phase
TEAE2513
TEAE related to study drug2213
Severe TEAE500
SAE000
SAE related to study drug000
AE leading to withdrawal300
AE leading to death000
Other pre-specifiedThe Purpose of This Study is to Estimate the Effect Size of Treatment on the PERMP Instrument in an Adult ADHD Population as Defined by the Inclusion/Exclusion Criteria.

The purpose of this study is to estimate the effect size of treatment on the PERMP instrument in an adult ADHD population as defined by the inclusion/exclusion criteria. The Permanent Product Measure of Performance (PERMP) is an objective, validated, skill-adjusted 10-minute math test that measures attention in ADHD. The PERMP correct score comprises the number of math problems answered correctly. A higher PERMP score indicates better performance.Though primary and secondary endpoints are defined in accordance with International Conference on Harmonization (ICH) E9 guidelines, this study is not intended to demonstrate statistical significance via treatment group comparisons.

Time frame:
Baseline (pre-dose) at Visit 8 then post-dose at hours .5,1,3,6,9,12,13,14,15, and 16.
Reported as:
Number · units on a scale
The Purpose of This Study is to Estimate the Effect Size of Treatment on the PERMP Instrument in an Adult ADHD Population as Defined by the Inclusion/Exclusion Criteria.
units on a scaleEffect Size (CTx-1301 - Placebo)
Hour .51.41
Hour 11.76
Hour 31.58
Hour 62.60
Hour 92.20
Hour 120.88
Hour 130.97
Hour 141.24
Hour 151.77
Hour 160.98

Adverse events

Collected over Screening (Visit 1) to Visit 9 (approximately. 7-11 weeks, depending on screening window). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase0/26 (0%)0/26 (0%)25/26 (96.2%)
CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Treatment Phase0/11 (0%)0/11 (0%)1/11 (9.1%)
Placebo0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent other events
Showing 10 of 40
Most frequent other events
EventCTx-1301 (Dexmethylphenidate Tablet) Dose Optimization PhaseCTx-1301 (Dexmethylphenidate Tablet) Double-Blind Treatment PhasePlacebo
Dry MouthGastrointestinal disorders15/260/110/10
AnxietyPsychiatric disorders11/260/110/10
InsomniaPsychiatric disorders11/260/110/10
Decreased AppetiteMetabolism and nutrition disorders10/260/110/10
HeadacheNervous system disorders8/260/111/10
IrritabilityPsychiatric disorders7/260/110/10
NauseaGastrointestinal disorders4/260/110/10
Feeling JitteryGeneral disorders4/260/110/10
Upper Respiratory Tract InfectionInfections and infestations4/260/110/10
Affect LabilityPsychiatric disorders3/260/110/10

Baseline characteristics

All subjects were titrated to their optimal dose during the dose-optimization phase. Each subject was expected to be on their optimal dose for 2 sequential weeks prior to the double-blind randomization phase. Subjects were randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase. As a result, 26 subjects entered the dose optimization phase and 21 completed the dose optimization phase. Twenty one subjects entered and completed the double-blind phase.

Age, Customized
Age, Customized(Participants)CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization PhaseCTx-1301 (Dexmethylphenidate Tablet) Double-Blind PeriodPlaceboTotal
18 to 55 Dose Optimization Phase260026
18 to 55 Double-Blind Treatment Phase0111021
Sex: Female, Male
Sex: Female, Male(Participants)CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization PhaseCTx-1301 (Dexmethylphenidate Tablet) Double-Blind PeriodPlaceboTotal
Dose Optimization Phase — Female19——19
Dose Optimization Phase — Male7——7
Double-Blind Phase — Female—10717
Double-Blind Phase — Male—134
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization PhaseCTx-1301 (Dexmethylphenidate Tablet) Double-Blind PeriodPlaceboTotal
Dose Optimization Phase — Hispanic or Latino7——7
Dose Optimization Phase — Not Hispanic or Latino19——19
Dose Optimization Phase — Unknown or Not Reported0——0
Double-Blind Phase — Hispanic or Latino—415
Double-Blind Phase — Not Hispanic or Latino—7916
Double-Blind Phase — Unknown or Not Reported—000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization PhaseCTx-1301 (Dexmethylphenidate Tablet) Double-Blind PeriodPlaceboTotal
Dose Optimization Phase — American Indian or Alaska Native0——0
Dose Optimization Phase — Asian3——3
Dose Optimization Phase — Native Hawaiian or Other Pacific Islander2——2
Dose Optimization Phase — Black or African American1——1
Dose Optimization Phase — White20——20
Dose Optimization Phase — More than one race0——0
Dose Optimization Phase — Unknown or Not Reported0——0
Double-Blind Phase — American Indian or Alaska Native—000
Double-Blind Phase — Asian—123
Double-Blind Phase — Native Hawaiian or Other Pacific Islander—112
Double-Blind Phase — Black or African American—101
Double-Blind Phase — White—8715
Double-Blind Phase — More than one race—000
Double-Blind Phase — Unknown or Not Reported—000
Region of Enrollment
Region of Enrollment(Participants)CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization PhaseCTx-1301 (Dexmethylphenidate Tablet) Double-Blind PeriodPlaceboTotal
United States260026
Region of Enrollment
Region of Enrollment(Participants)CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization PhaseCTx-1301 (Dexmethylphenidate Tablet) Double-Blind PeriodPlaceboTotal
United States0111021
08

Study locations

1 site
  • Clinical Research of Southern Nevada, LLC
    Las Vegas, Nevada 89128, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jun 2023, 5 months.

Results were first posted in Jul 2026, 3 years after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 5 months is below that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2022
First posted
Nov 30, 2022
StartActual
Dec 29, 2022
Primary completionActual
Jun 13, 2023
CompletionActual
Jun 13, 2023
Results first posted
Jul 2, 2026
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05631626
Lead sponsor
Cingulate Therapeutics
Collaborators
Rho, Inc.
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Dec 29, 2022
Primary completion
Jun 13, 2023
Completion
Jun 13, 2023
Results posted
Jul 2, 2026
Last update
Jul 2, 2026

Study contacts

Ann Childress, MD
principal investigator · Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CTX-1301

Start the discussion